Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
Status:
Terminated
Trial end date:
2014-12-11
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, Phase Ib dose escalation study of Oxcarbazepine with
morphine in patients with refractory cancer pain. The primary endpoint is to evaluate the
safety and toxicity of the combination of Oxcarbazepine plus morphine. The secondary
endpoints are improving pain control, reduce morphine use and improve the quality of life.